Brian C. Mansfield

Brian C. Mansfield

Auto-generated profile, based on publicly available information

Brian C. Mansfield

Section on Cellular Differentiation, Division of Translational Medicine Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health Bethesda Maryland USA

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2002 in Current Molecular Medicine
Verified
Journal Article
Closed access
PDF file
JCJanice Yang Chou
Janice Yang Chou
DMDietrich Matern
Dietrich Matern
BMBrian C. Mansfield
Brian C. Mansfield
YCYuan-Tsong Chen
Yuan-Tsong Chen
Glycogen storage disease type I (GSD-I) is a group of autosomal recessive disorders with an incidence of 1 in 100,000. The two major subtypes are GSD-Ia (MIM232200), caused by a deficiency of glucose-6-phosphatase (G6Pase), and GSD-Ib (MIM232220), caused by a deficiency in the glucose-6-phosphate transporter (G6PT). Both G6Pase and G6PT are associated with the endoplasmic reticulum (ER) membrane. G6PT translocates glucose-6-phosphate (G6P) from the cytoplasm into the lumen of the ER, where G6Pase hydrolyses the G6P into glucose and phosphate. Together G6Pase and G6PT maintain glucose homeostasis. G6Pase is expressed in gluconeogenic tissues, the liver, kidney, and intestine. However G6PT, which transports G6P efficiently only in the presence of G6Pase, is expressed ubiquitously. This suggests that G6PT may play other roles in tissues lacking G6Pase. Both GSD-Ia and GSD-Ib patients manifest phenotypic G6Pase deficiency, characterized by growth retardation, hypoglycemia, hepatomegaly, nephromegaly, hyperlipidemia, hyperuricemia, and lactic academia and the current treatment is a dietary therapy. GSD-Ib patients also suffer from chronic neutropenia and functional deficiencies of neutrophils and monocytes, which is treated with granulocyte colony stimulating factor to restore myeloid function. The GSD-Ia and GSDIb genes have been cloned. To date, 76 G6Pase and 69 G6PT mutations have been identified in GSDI patients. A database of the residual enzymatic activity retained by the G6Pase missense mutants is facilitating the correlation of the disease phenotype with the patients genotype. While the molecular basis for the GSD-I disorders are now known and symptomatic therapies are available, many aspects of the diseases are still poorly understood, and there are no cures. Recently developed animal models of the disorders are now being exploited to delineate the disease more precisely and develop new, more causative therapies.

26 October 2010 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
PDF file
JCJanice Y. Chou
Janice Y. Chou
HJHyun Sik Jun
Hyun Sik Jun
BMBrian C. Mansfield
Brian C. Mansfield

1 June 1996 in Nature Genetics
Verified
Journal Article
Open access
KLKe-Jian Lei
Ke-Jian Lei
HCHungwen Chen
Hungwen Chen
CPChi-Jiunn Pan
Chi-Jiunn Pan
JWJerrold M. Ward
Jerrold M. Ward
BMBedrich Mosinger
Bedrich Mosinger
JCJanice Yang Chou
Janice Yang Chou
Glycogen storage disease type 1a (GSD-1a) is caused by a deficiency in microsomal glucose-6-phosphatase (G6Pase), the key enzyme in glucose homeostasis. A G6Pase knockout mouse which mimics the pathophysiology of human GSD-1a patients was created to understand the pathogenesis of this disorder, to delineate the mechanisms of G6Pase catalysis, and to develop future therapeutic approaches. By examining G6Pase in the liver and kidney, the primary gluconeogenic tissues, we demonstrate that glucose-6-P transport and hydrolysis are performed by separate proteins which are tightly coupled. We propose a modified translocase catalytic unit model for G6Pase catalysis.

30 April 2008 in Human Mutation
Verified
Journal Article
Open access
PDF file
JCJanice Y. Chou
Janice Y. Chou
BMBrian C. Mansfield
Brian C. Mansfield
Glucose‐6‐phosphatase‐α (G6PC) is a key enzyme in glucose homeostasis that catalyzes the hydrolysis of glucose‐6‐phosphate to glucose and phosphate in the terminal step of gluconeogenesis and glycogenolysis. Mutations in the G6PC gene, located on chromosome 17q21, result in glycogen storage disease type Ia (GSD‐Ia), an autosomal recessive metabolic disorder. GSD‐Ia patients manifest a disturbed glucose homeostasis, characterized by fasting hypoglycemia, hepatomegaly, nephromegaly, hyperlipidemia, hyperuricemia, lactic acidemia, and growth retardation. G6PC is a highly hydrophobic glycoprotein, anchored in the membrane of the endoplasmic reticulum with the active center facing into the lumen. To date, 54 missense, 10 nonsense, 17 insertion/deletion, and three splicing mutations in the G6PC gene have been identified in more than 550 patients. Of these, 50 missense, two nonsense, and two insertion/deletion mutations have been functionally characterized for their effects on enzymatic activity and stability. While GSD‐Ia is not more prevalent in any ethnic group, mutations unique to Caucasian, Oriental, and Jewish populations have been described. Despite this, GSD‐Ia patients exhibit phenotypic heterogeneity and a stringent genotype–phenotype relationship does not exist. Hum Mutat 29(7), 921–930, 2008. Published 2008 Wiley‐Liss, Inc.

7 October 2014 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
JCJanice Y. Chou
Janice Y. Chou
HJHyun Sik Jun
Hyun Sik Jun
BMBrian C. Mansfield
Brian C. Mansfield

1 March 2007 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YCYuk Yin Cheung
Yuk Yin Cheung
SKSo Youn Kim
So Youn Kim
WYWai Han Yiu
Wai Han Yiu
CPChi-Jiunn Pan
Chi-Jiunn Pan
HJHyun-Sik Jun
Hyun-Sik Jun
JCJanice Y. Chou
Janice Y. Chou
Neutropenia and neutrophil dysfunction are common in many diseases, although their etiology is often unclear. Previous views held that there was a single ER enzyme, glucose-6-phosphatase–α (G6Pase-α), whose activity — limited to the liver, kidney, and intestine — was solely responsible for the final stages of gluconeogenesis and glycogenolysis, in which glucose-6-phosphate (G6P) is hydrolyzed to glucose for release to the blood. Recently, we characterized a second G6Pase activity, that of G6Pase-β (also known as G6PC), which is also capable of hydrolyzing G6P to glucose but is ubiquitously expressed and not implicated in interprandial blood glucose homeostasis. We now report that the absence of G6Pase-β led to neutropenia; defects in neutrophil respiratory burst, chemotaxis, and calcium flux; and increased susceptibility to bacterial infection. Consistent with this, G6Pase-β–deficient (G6pc3–/–) mice with experimental peritonitis exhibited increased expression of the glucose-regulated proteins upregulated during ER stress in their neutrophils and bone marrow, and the G6pc3–/– neutrophils exhibited an enhanced rate of apoptosis. Our results define a molecular pathway to neutropenia and neutrophil dysfunction of previously unknown etiology, providing a potential model for the treatment of these conditions.